The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Stage I findings of a two-stage phase II study to assess the efficacy, safety, and tolerability of barasertib (AZD1152) compared with low-dose cytosine arabinoside (LDAC) in elderly patients (pts) with acute myeloid leukemia (AML).
Giovanni Martinelli
No relevant relationships to disclose
Hagop Kantarjian
Research Funding - AstraZeneca
Elias Jabbour
No relevant relationships to disclose
Alfonso Quintas-Cardama
No relevant relationships to disclose
Kiyoshi Ando
No relevant relationships to disclose
Jacques-Olivier Bay
No relevant relationships to disclose
Andrew Wei
Research Funding - Celgene
Stefanie Gröpper
No relevant relationships to disclose
Kate Owen
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Laura Pike
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Nicola Schmitt
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Paul Stockman
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Aristoteles Giagounidis
No relevant relationships to disclose